Journal
IMMUNOTHERAPY
Volume 10, Issue 16, Pages 1349-1360Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2018-0078
Keywords
cancer immunology; cancer vaccines; DNA plasmid; gene therapy; immunotherapy; molecular immunology; nanoparticles; non-small-cell lung cancer; vaccine vectors
Categories
Funding
- American Cancer Society [98-277-10]
Ask authors/readers for more resources
Aim: Lung cancer gene therapies require reagents to selectively transfect lung tumors after systemic administration. Materials & methods: We created a reagent called NSCLC-NP by attaching a peptide with binding affinity for lung cancer to polyamidoamine dendrimers. The positively charged dendrimers electrostatically bind negatively charged nucleic acids, inhibit endogenous nucleases and transfect cells targeted by the attached peptide. Results:In vitro, NSCLC-NP complexed to DNA plasmids bound and transfected three human lung cancer cell lines producing protein expression of the plasmid's gene. In vivo, systemically administered NSCLC-NP selectively transfected lung cancer cells growing in RAG1KO mice. Conclusion: The capability of NSCLC-NP to selectively transfect lung cancer allows its future use as a vehicle to implement human lung cancer gene therapy strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available